Format

Send to

Choose Destination
Hum Vaccin Immunother. 2016 Mar 3;12(3):664-7. doi: 10.1080/21645515.2015.1086048.

Potential protective immunogenicity of tetanus toxoid, diphtheria toxoid and Cross Reacting Material 197 (CRM197) when used as carrier proteins in glycoconjugates.

Author information

1
a GSK Vaccines GmbH , Marburg , Germany.

Abstract

When tetanus toxoid (TT), diphtheria toxoid (DT) or Cross Reacting Material 197 (CRM197), a non-toxic diphtheria toxin mutant protein, are used as carrier proteins in glycoconjugate vaccines, these carriers induce a protein specific antibody response as measured by in vitro assays. Here, it was evaluated whether or not glycoconjugates based on TT, DT or CRM197 can induce a protective immune response as measured by potency tests according to the European Pharmacopoeia. It could be shown, that the conjugate carriers TT and DT can induce a protective immune response against a lethal challenge by toxins in animals, while glycoconjugates based on CRM197 failed to induce a protective immune response. Opportunities for new applications of glycoconjugates are discussed.

KEYWORDS:

Cross Reacting Material 197; carrier proteins; combination vaccines; diphtheria toxoid; glycoconjugates; protective immunity; tetanus toxoid

PMID:
26327602
PMCID:
PMC4964734
DOI:
10.1080/21645515.2015.1086048
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center